Connection

Robert Harrington to Tyrosine

This is a "connection" page, showing publications Robert Harrington has written about Tyrosine.
Connection Strength

0.881
  1. Glycoprotein IIb/IIIa receptor antagonists: a comparative review of their use in percutaneous coronary intervention. Am J Cardiovasc Drugs. 2003; 3(6):423-36.
    View in: PubMed
    Score: 0.200
  2. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide. Circulation. 2002 Sep 17; 106(12):1470-6.
    View in: PubMed
    Score: 0.196
  3. Upstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trials. Circ Cardiovasc Qual Outcomes. 2011 Jul; 4(4):448-58.
    View in: PubMed
    Score: 0.090
  4. Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008 Jun; 133(6 Suppl):670S-707S.
    View in: PubMed
    Score: 0.073
  5. Comparison of ST-segment resolution with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy versus fibrinolytic alone (data from four clinical trials). Am J Cardiol. 2005 Mar 01; 95(5):611-4.
    View in: PubMed
    Score: 0.058
  6. Combined assessment of thrombolysis in myocardial infarction flow grade, myocardial perfusion grade, and ST-segment resolution to evaluate epicardial and myocardial reperfusion. Am J Cardiol. 2004 Jun 01; 93(11):1362-7, A5-6.
    View in: PubMed
    Score: 0.055
  7. Troponin T and quantitative ST-segment depression offer complementary prognostic information in the risk stratification of acute coronary syndrome patients. J Am Coll Cardiol. 2003 Feb 05; 41(3):371-80.
    View in: PubMed
    Score: 0.050
  8. Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B). Am Heart J. 2002 Dec; 144(6):995-1002.
    View in: PubMed
    Score: 0.050
  9. An automated strategy for bedside aPTT determination and unfractionated heparin infusion adjustment in acute coronary syndromes: insights from PARAGON A. J Thromb Thrombolysis. 2002 Aug; 14(1):33-42.
    View in: PubMed
    Score: 0.048
  10. Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Am Heart J. 2016 Jul; 177:1-8.
    View in: PubMed
    Score: 0.031
  11. Timing of glycoprotein IIb/IIIa inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (results from CRUSADE). Am J Cardiol. 2007 May 15; 99(10):1389-93.
    View in: PubMed
    Score: 0.017
  12. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study. Am Heart J. 2003 Oct; 146(4):628-34.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.